Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

000963 Huadong Medicine Co.,Ltd.

Trading 10-23 13:18:27

26.21

+0.21

+0.81%

High26.24	Low25.63	Vol8.27M
Open25.80	D1 Closing26.00	Amplitude2.35%
Mkt Cap45.97B	Tradable Cap45.95B	Total Shares1.75B
T/O214.00M	T/O Rate0.47%	Tradable Shares1.75B
P/B1.79	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"000963","market":"SZ","secType":"STK","nameCN":"Huadong Medicine Co.,Ltd.","latestPrice":26.21,"timestamp":1792732707000,"preClose":26,"halted":0,"volume":8273449,"delay":0,"changeRate":0.0081,"floatShares":1753000000,"shares":1754000000,"eps":1.9731,"marketStatus":"Trading","change":0.21,"latestTime":"10-23 13:18:27","open":25.8,"high":26.24,"low":25.63,"amount":214000000,"amplitude":0.0235,"askPrice":26.22,"askSize":7,"bidPrice":26.21,"bidSize":28,"shortable":0,"etf":0,"ttmEps":1.9731,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1792738800000},"marketStatusCode":2,"adr":0,"adjPreClose":26,"symbolType":"stock","openAndCloseTimeList":[[1792719000000,1792726200000],[1792731600000,1792738800000]],"highLimit":28.6,"lowLimit":23.4,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1753736848,"isCdr":false,"pbRate":1.79,"roa":"--","peRate":13.283665,"roe":"7.31%","epsLYR":1.9484,"committee":-0.403107,"marketValue":45965000000,"turnoverRate":0.0047,"status":0,"floatMarketCap":45946000000},"requestUrl":"/m/hq/s/000963/wiki","defaultTab":"wiki","newsList":[{"id":"2676431570","title":"Huadong Medicine's Unit Gets Nod for DR30206's Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2676431570","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676431570?lang=en_us&edition=fundamental","pubTime":"2026-10-19 13:44","pubTimestamp":1792388641,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Zhejiang Daer Biotechnology, received approval from China's National Medical Products Administration for the clinical trial of DR30206, according to a Shenzhen bourse filing over the weekend.The Chinese drugmaker's shares rose 1% during Monday's afternoon trade.The drug is developed as a treatment for patients with locally advanced or unresectable Stage III non-small cell lung cancer.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0132","000963","BK0188","LU1969619763.USD","BK0209","LU2328871848.SGD","BK0183","BK0175","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675470382","title":"Huadong Medicine's Unit Gets Nod to Trial Head, Neck Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2675470382","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675470382?lang=en_us&edition=fundamental","pubTime":"2026-10-13 11:25","pubTimestamp":1791861907,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  unit, Zhejiang Doer Biologics, has received clinical trial approval from China's National Medical Products Administration for DR30206 for injection, according to a Tuesday filing on the Shenzhen bourse.The drug will be evaluated as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma in combination with chemotherapy.The Chinese drugmaker's shares fell over 1% Tuesday morning in Shenzhen.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0209","BK0188","LU2328871848.SGD","BK0175","LU1969619763.USD","BK0132","BK0196","BK0187","BK0183","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159133157","title":"Huadong Medicine's Shangkelin Spray Wins Recommendations in Two Authoritative Guidelines, Further Validating Evidence-Based Value of Miao Ethnic External Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=1159133157","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159133157?lang=en_us&edition=fundamental","pubTime":"2026-10-07 12:28","pubTimestamp":1791347307,"startTime":"0","endTime":"0","summary":"According to a report from Zhitong Finance APP, on October 7, Huadong Medicine Co.,Ltd. (000963.SZ) announced that its wholly-owned subsidiary Huadong Medicine (Guizhou) Pharmaceutical Co., Ltd.'s...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","LU2328871848.SGD","000963","BK0209","BK0188","BK0175","LU1969619763.USD","BK0187","BK0132","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153431292","title":"Huadong Medicine's HDM1002 Tablet Achieves Topline Results: What Is Its Future Commercial Value?","url":"https://stock-news.laohu8.com/highlight/detail?id=1153431292","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153431292?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:40","pubTimestamp":1790646038,"startTime":"0","endTime":"0","summary":"Recently, Huadong Medicine Co.,Ltd. (SZSE: 000963) announced that its wholly owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical had achieved positive topline results in the China Phase III...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000963","BK0175","LU1969619763.USD","BK0183","BK0188","BK0132","BK0209","BK0196","BK0187","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670854852","title":"Huadong Medicine's Weight Management Drug Shows 'Positive' Results in Third Phase Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2670854852","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670854852?lang=en_us&edition=fundamental","pubTime":"2026-09-28 12:42","pubTimestamp":1790570575,"startTime":"0","endTime":"0","summary":"Huadong Medicine  said the third phase trial of HDM1002 for weight management showed \"positive topline\" results.At Week 52, the 200-milligram and 400-milligram doses achieved mean weight reductions of 10.7% and 12.2%, versus 1.2% for placebo, according to a Monday filing with the Shenzhen bourse.The drug also reduced liver fat, improved liver enzymes and optimized body composition.Shares of the drugmaker were up 3% in recent trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0187","BK0175","BK0209","BK0196","BK0132","BK0188","BK0183","LU1969619763.USD","LU2328871848.SGD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193910142","title":"Huadong Medicine's Innovative Oral Small Molecule GLP-1 Agonist HDM1002 Achieves Positive Phase III Weight Loss Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1193910142","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193910142?lang=en_us&edition=fundamental","pubTime":"2026-09-27 18:48","pubTimestamp":1790506091,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) has announced that its wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. has obtained positive topline results from the Phase III...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000963","BK0175","LU1969619763.USD","BK0183","BK0188","BK0132","JDOC","BK0209","BK0196","BK0187","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667016614","title":"Chinese Drug Regulator Accepts Huadong Medicine's Registration Application for Primelase Semiconductor Laser Therapy System","url":"https://stock-news.laohu8.com/highlight/detail?id=2667016614","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667016614?lang=en_us&edition=fundamental","pubTime":"2026-09-15 15:24","pubTimestamp":1789457072,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted Huadong Medicine's  application for the registration of its Primelase Semiconductor Laser Therapy System, according to a Shenzhen bourse filing on Tuesday.Primelase, which is developed by subsidiary High Technology Products, is a semiconductor laser multi-parameter adjustable therapeutic device,The drugmaker's shares slipped 1% at the close.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0196","BK0183","BK0209","LU1969619763.USD","BK0175","LU2328871848.SGD","BK0132","BK0188","BK0187","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662685400","title":"Heidelberg Pharma, Huadong Medicine Expand ADC Collaboration to Develop New Drug Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2662685400","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662685400?lang=en_us&edition=fundamental","pubTime":"2026-08-28 16:48","pubTimestamp":1787906903,"startTime":"0","endTime":"0","summary":"Heidelberg Pharma, Huadong Medicine expand ADC collaboration to develop new drug candidatesHeidelberg Pharma broadened its strategic partnership with Huadong Medicine via a new joint R&D collaboration","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDL5n3Ls1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0187","BK0175","BK0209","BK0196","BK0132","BK0188","BK0183","LU1969619763.USD","LU2328871848.SGD","000963"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662720197","title":"China NMPA Clears Heidelberg Pharma’s HDP-101 Combo Trial in Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2662720197","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662720197?lang=en_us&edition=fundamental","pubTime":"2026-08-27 17:15","pubTimestamp":1787822154,"startTime":"0","endTime":"0","summary":"China NMPA clears Heidelberg Pharma’s HDP-101 combo trial in multiple myelomaChina’s NMPA cleared a Phase Ib/II combination trial of Heidelberg Pharma’s HDP-101 in relapsed or refractory multiple myel","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260827:nNDL20wNHl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","BK0209","BK0196","BK0132","LU2328871848.SGD","000963","BK0183","BK0175","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662771864","title":"Huadong Medicine's H1 Profit Rises 3%, Revenue Climbs 2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662771864","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662771864?lang=en_us&edition=fundamental","pubTime":"2026-08-27 16:04","pubTimestamp":1787817868,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  net profit attributable to shareholders in the first half rose 2.5% to 1.86 billion yuan from 1.81 billion yuan a year earlier, according to a Shenzhen bourse filing on Thursday.Earnings per share increased 2.6% year on year to 1.06 yuan from 1.03 yuan.Operating revenue climbed 1.8% to 22.1 billion yuan from 21.7 billion yuan in the previous year.The Chinese drugmaker proposed to distribute a cash dividend of 3.50 yuan per 10 shares to shareholders.The company's shares rose 1% at the close.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1969619763.USD","BK0209","FCA","BK0175","000963","BK0132","BK0183","LU2328871848.SGD","BK0187","BK0188","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662779426","title":"Huadong Medicine's Lymphoma Drug Gets US FDA's Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2662779426","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662779426?lang=en_us&edition=fundamental","pubTime":"2026-08-27 15:58","pubTimestamp":1787817488,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  HDM2005 for injection obtained a fast track designation from the U.S. Food and Drug Administration, according to a Shenzhen bourse filing on Thursday.The drug is being developed as a treatment for patients with relapsed or refractory mantle cell lymphoma, who had at least two lines of systemic therapy, including a BTK inhibitor.The Chinese drugmaker's shares rose 1% at the close.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0188","LU2328871848.SGD","BK0196","LABU","BK0132","BK0175","BK0187","BK0209","000963","BK4585","LU1969619763.USD","BK0183","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662279714","title":"Huadong Medicine H1 Net Profit up 2.53% Y/Y","url":"https://stock-news.laohu8.com/highlight/detail?id=2662279714","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662279714?lang=en_us&edition=fundamental","pubTime":"2026-08-26 18:19","pubTimestamp":1787739542,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260826:nL4N44N0OT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2328871848.SGD","000963","BK0175","BK0196","BK0209","BK0187","BK0183","BK0132","BK0188","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662989157","title":"Huadong Medicine Secures China Regulatory Nod For Undereye Filler","url":"https://stock-news.laohu8.com/highlight/detail?id=2662989157","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662989157?lang=en_us&edition=fundamental","pubTime":"2026-08-26 14:56","pubTimestamp":1787727365,"startTime":"0","endTime":"0","summary":"Huadong Medicine's (SHE:000963) UK-based aesthetic subsidiary Sinclair Pharmaceuticals has received approval from China's National Medical Products Administration for its undereye filler, MaiLiPrecise","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1969619763.USD","000963","BK0196","BK0209","LU2328871848.SGD","BK0132","BK0188","BK0175","BK0187","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660241822","title":"Press Release: CARsgen Therapeutics Announces 2026 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2660241822","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660241822?lang=en_us&edition=fundamental","pubTime":"2026-08-19 08:15","pubTimestamp":1787098500,"startTime":"0","endTime":"0","summary":"SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, has announced its 2026 Interim Results.Business Highlights-- Cash and cash equivalents were around RMB1,400 million as of June 30,2026. Cash and cash equivalents at the end of 2026 are expected to be not. less than RMB1,200 million. In light of operational factors, we expect to. -- During H1, 2026, CARsgen has received a total of 110 confirmed orders of. -- Satri-cel receives NMPA approval in June 2026 as world's first and only. CAR-T for solid tumors. Data of satri-cel as sequential therapy after 1L. treatment in patients with G/GEJA have been presented at the 2026 ASCO. -- Multiple allogeneic CAR T-cell products are under development based on. the proprietary THANK--u Plus platform. Among them, research results. for CT0596 in the treatment of R/R MM and PCL, as well as for CT1190B in. the treatment of R/R B--NHL, have been presented at the E","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1929549753.HKD","LU2506952097.USD","LU0942090050.USD","BK4534","IE00B3PB1722.GBP","SG9999001440.SGD","LU0950375773.USD","LU1032955483.USD","CSCS","CSCL","LU0868494617.USD","LU1221951129.SGD","LU2328871848.SGD","BK4560","PC","R","SG9999001424.SGD","LU1430594728.SGD","IE00BVYPNV92.GBP","LU2237443465.HKD","LU2237443622.USD","LENZ","BK4022","AIQ","03160","BK1574","BK0187","LU2417539215.USD","LU1599440770.SGD","IE00B1BXHZ80.USD","BK4515","BK0209","CIBR","BK4230","LU0070302665.USD","TM","IE00B42XCP33.USD","LU2462157665.USD","LU0823417653.USD","02171","CAR","BK4533","IYZ","CSCO","LU0203345920.USD","LU1046421795.USD","BK4612","000963","LU1674673428.USD","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660544493","title":"CARsgen FY26 H1 Net Loss Narrows to RMB 70.84 Million; Revenue Rises 21.49% to RMB 61.92 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2660544493","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660544493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:28","pubTimestamp":1787063306,"startTime":"0","endTime":"0","summary":"CARsgen FY26 H1 net loss narrows to RMB 70.84 million; revenue rises 21.49% to RMB 61.92 millionCARsgen posted revenue of RMB 62 million, up 21.58% year over year, driven mainly by zevor-cel sales vol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLbGD37X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","LU2328871848.SGD","BK0196","BK1161","BK0188","LU1969619763.USD","BK1574","BK0209","BK1585","02171","BK0187","BK0132","BK1587","000963","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658027106","title":"Huadong Medicine's UK Arm Receives EU Certification for Intradermal Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2658027106","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658027106?lang=en_us&edition=fundamental","pubTime":"2026-08-10 13:04","pubTimestamp":1786338280,"startTime":"0","endTime":"0","summary":"Huadong Medicine's  UK subsidiary, Sinclair Pharma, received European Union CE certification for its carboxymethyl chitosan injection solution, according to a Monday filing with the Shenzhen bourse.The product can be marketed in the EU, Huadong said.The product, branded Kytogen Defend, is indicated for intradermal injection, superficial filling, skin texture improvement and skin hydration, the company said. KIO015 is the product's development code.The product is the first of its kind not derived from animal products, Huadong said.Shares of the pharmaceutical company rose 2% in recent trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0187","BK0188","BK4156","BK0196","BK0209","LU1969619763.USD","BK0132","BK0183","LU2328871848.SGD","000963","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145023735","title":"Huadong Medicine Subsidiary Secures EU MDR CE Certification for Medical Device","url":"https://stock-news.laohu8.com/highlight/detail?id=1145023735","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145023735?lang=en_us&edition=fundamental","pubTime":"2026-08-09 16:40","pubTimestamp":1786264814,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. (000963.SZ) announced that its wholly-owned UK subsidiary, Sinclair Pharma Limited (\"Sinclair\"), has obtained EU MDR CE certification for KIO015, a novel injectable...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LNGR","BK0188","159883","BK0187","GDOC","BK0196","CE","BK0132","PTH","000963","MEDX","LU2328871848.SGD","BK1100","FESXmain","RSPH","PSCM","HART","LGHT","BK4585","BK1574","BK4588","BK1583","BK4109","BK0209","BK0175","FSXEmain","IEIH","AGNG","MDEV","09996","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110023769","title":"Centralised Drug Procurement Exposes Mixed Results for Huadong Medicine, Generic Drug Division Faces Pressure Amid Transformation Hurdles","url":"https://stock-news.laohu8.com/highlight/detail?id=1110023769","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110023769?lang=en_us&edition=fundamental","pubTime":"2026-08-07 10:50","pubTimestamp":1786071031,"startTime":"0","endTime":"0","summary":"Huadong Medicine Co.,Ltd. recently announced the preliminary results of the 12th round of national centralised drug procurement, winning bids for three products while losing bids for four core drugs....","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0183","LU2328871848.SGD","BK0187","LU1969619763.USD","BK0188","BK0132","BK0209","000963","BK0175","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656340363","title":"Huadong Medicine Wins Pre-Bids for Three Drugs Under China Procurement System","url":"https://stock-news.laohu8.com/highlight/detail?id=2656340363","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656340363?lang=en_us&edition=fundamental","pubTime":"2026-08-03 12:40","pubTimestamp":1785732011,"startTime":"0","endTime":"0","summary":"Huadong Medicine  won pre-bids for three of its products under China's drug procurement program, according to a Monday disclosure to the Shanghai bourse.The pre-selected drugs include the cyclosporine soft capsules and tacrolimus capsules for immunology, as well as mesalazine enteric-coated tablets for inflammatory bowel diseases.Total sales of its winning products reached 2.08 billion yuan in 2025.Shares fell 2% during the midday break on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","BK0183","BK0175","000963","BK0188","LU1969619763.USD","BK0187","BK0196","BK0132","BK0209"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120367878","title":"Huadong Medicine Chairman Proposes Interim Dividend Plan for 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1120367878","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120367878?lang=en_us&edition=fundamental","pubTime":"2026-07-20 12:01","pubTimestamp":1784520082,"startTime":"0","endTime":"0","summary":"An announcement from Huadong Medicine Co.,Ltd. (SZSE: 000963) reveals a proposal by the company's Chairman, Mr. Lv Liang.The proposal, made under the authority granted by the 2025 annual general...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0175","000963","BK0183","BK0209","BK0188","BK0132","LU1969619763.USD","BK0187","BK0196","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1792732709343,"stockEarnings":[{"period":"1week","weight":-0.0114},{"period":"1month","weight":-0.0233},{"period":"3month","weight":-0.0779},{"period":"6month","weight":-0.235},{"period":"1year","weight":-0.3267},{"period":"ytd","weight":-0.3178}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0744},{"period":"3month","weight":-0.0409},{"period":"6month","weight":-0.1034},{"period":"1year","weight":-0.0653},{"period":"ytd","weight":-0.0783}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"华东医药股份有限公司","boardCode":"AI0052","boardName":"零售业","stockholders":"100196人(较上一季度增加18.85%)","perCapita":"17495股","listingDate":"2000-01-27","address":"浙江省杭州市拱墅区中山北路439号4、7楼","registeredCapital":"175373万元","survey":"　　华东医药股份有限公司的主营业务是专科、慢病及特殊用药领域的研发、生产和销售。公司的主要产品是慢性肾病用药、免疫用药、肿瘤用药、内分泌用药、消化系统用药、心血管用药。","listedPrice":5.76},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Huadong Medicine Co.,Ltd.,000963,Huadong Medicine Co.,Ltd.股票,Huadong Medicine Co.,Ltd.股票老虎,Huadong Medicine Co.,Ltd.股票老虎国际,Huadong Medicine Co.,Ltd.行情,Huadong Medicine Co.,Ltd.股票行情,Huadong Medicine Co.,Ltd.股价,Huadong Medicine Co.,Ltd.股市,Huadong Medicine Co.,Ltd.股票价格,Huadong Medicine Co.,Ltd.股票交易,Huadong Medicine Co.,Ltd.股票购买,Huadong Medicine Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Huadong Medicine Co.,Ltd.(000963),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Huadong Medicine Co.,Ltd.(000963) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction